Download or read book Biotechnology Valuation written by Karl Keegan and published by John Wiley & Sons. This book was released on 2009-01-15 with total page 216 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start." —Chris Blackwell, Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." —Steve Winokur, Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." —Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." —Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company

Download or read book Biotechnology Valuation Investing written by Jason Hsu and published by Independently Published. This book was released on 2019-03-16 with total page 166 pages. Available in PDF, EPUB and Kindle. Book excerpt: The selection of biotech stocks for investment is more difficult compared with the selection of other stocks and industries that possess historical data, since biotechnology is a recently new science. In the first edition of this book, we described the crucial parameters for the valuation of an early stage biotech company without a drug in the market. In this edition, we analyze novel financial models that can value stocks of biotech companies with products in the market or products under development (in pre-clinical and clinical studies). All of these parameters should be helpful to potential new investors when creating a stock portfolio that includes highly promising biotech companies. Our strategy of selecting highly promising stocks based on all parameters described in this book and of performing a basic financial modeling analysis with DFC and/or real options valuation models has proven very successful, as this strategy provides returns higher than 100% in most cases. In the first edition of this book, based on our strategy, we suggested that Juno Therapeutics and Kite Pharma were "hot" stocks. At that time, Kite's stock was $50.19, while Juno's stock was $54.21. Since then, Kite's stock reached $179.79, with the company acquired by Gilead for $11.9 billion, while Juno's stock reached $86.96, with the company acquired by Celgene for $9 billion. Furthermore, Moderna Therapeutics, a private company that we valued at $5.5 billion in 2016 based on our real options financial model, today has a $7.5 billion valuation. This newly revised and expanded version was written to help investors in the selection of biotech stocks based on different scientific and financial criteria.

Download or read book Valuation in Life Sciences written by Boris Bogdan and published by Springer Science & Business Media. This book was released on 2010-04-19 with total page 378 pages. Available in PDF, EPUB and Kindle. Book excerpt: Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.

Download or read book Preserving the Promise written by Scott Dessain and published by Academic Press. This book was released on 2016-10-05 with total page 277 pages. Available in PDF, EPUB and Kindle. Book excerpt: Preserving the Promise: Improving the Culture of Biotech Investment critically examines why most biotech startups fail, as they emerge from universities into an ecosystem that inhibits rather than encourages innovation. This "Valley of Death" squanders our public investments in medical research and with them, the promise of longer and healthier lives. The authors explicate the Translation Gap faced by early stage biotech companies, the result of problematic technology transfer and investment practices, and provide specific prescriptions for improving translation of important discoveries into safe and effective therapies. In Preserving the Promise, Dessain and Fishman build on their collective experience as company founders, healthcare investor (Fishman) and physician/scientist (Dessain). The book offers a forward-looking, critical analysis of "conventional wisdom" that encumbers commercialization practices. It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives. - Explains why translation of biotech discovery into medicine succeeds so infrequently that it's been dubbed the Valley of Death - Uncovers specific decision-making strategies that more effectively align incentives, improving clinical and financial outcomes for investors, inventor/entrepreneurs, and patients - Examines the critical, early stages of commercialization, where technology transfer offices and Angels act as gatekeepers to development, and where tension between short-term financial and long-term clinical aspirations sinks important technologies - Deconstructs the forces driving biotech, recasts them in a proven conceptual framework, and offers practical guidance for making the system better

Download or read book The Biotech Investor s Bible written by George Wolff and published by John Wiley & Sons. This book was released on 2001-06-13 with total page 374 pages. Available in PDF, EPUB and Kindle. Book excerpt: A one-stop source for investing in biotech-with detailed coverage of the science, the business, the players, and the strategies for one of today's most promising (and volatile) industries To invest in biotech is to invest in the future, and as such, investors need to learn the nuances of the science they're putting their money on. The core asset of biotech companies is knowledge, and sound investment decisions are impossible without an understanding of this complex science. That's where The Biotech Investor's Bible fits in. This much-needed, one-of-a-kind resource simplifies the complex science surrounding the business of biotech and clarifies subtle distinctions within the context of their financial repercussions. The book explains the basics of genetics, patents, and therapies; and teaches investors how to value biotech companies and their state-of-the art products and technology. The Biotech Investor's Bible offers an informative summary of the relatively short history of the industry and provides a comprehensive review of various industry sectors.

Download or read book Biotechnology Venture Capital Investments written by William Blake Winchell and published by . This book was released on 2007-04-01 with total page 151 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book The Pharmagellan Guide to Biotech Forecasting and Valuation written by Frank S. David and published by Pharmagellan, LLC. This book was released on 2017-01-06 with total page 138 pages. Available in PDF, EPUB and Kindle. Book excerpt: If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. The Pharmagellan Guide is a comprehensive, thoroughly referenced handbook for early-stage biopharma assets and companies.

Download or read book From Breakthrough to Blockbuster written by Donald L. Drakeman and published by Oxford University Press. This book was released on 2022 with total page 241 pages. Available in PDF, EPUB and Kindle. Book excerpt: "Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--

Download or read book The Biotech Investor written by Tom Abate and published by Times Books. This book was released on 2013-08-13 with total page 308 pages. Available in PDF, EPUB and Kindle. Book excerpt: A sophisticated investor's practical tool kit for analyzing the science, business, opportunities, and risks in the century's most promising industry The world is entering a biotechnology boom-but only informed investors will prosper in the incredibly complex biotech business. Separating the bioengineered wheat from the chaff, San Francisco Chronicle science and technology columnist Tom Abate, one of the top objective authorities on biotech, gives investors the analytical foundation to understand the science, finances, time horizon, and technological and commercial potential of this burgeoning industry. In The Biotech Investor, Abate provides sophisticated business analysis, guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He explains how breaking news, medical conferences, U.S. Food and Drug Administration approvals, and the patent process affect investing strategies. Finally, he looks beyond medicine to review the financial opportunities presented by biotechnology advances in everything from agriculture to jean manufacturing, and shows investors how to identify "coattail" industries such as instrumentation and software development that will benefit from biotech successes. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.

Download or read book Science Business written by Gary P. Pisano and published by Harvard Business Press. This book was released on 2006 with total page 278 pages. Available in PDF, EPUB and Kindle. Book excerpt: Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance.

Download or read book Healthcare Investing Profiting from the New World of Pharma Biotech and Health Care Services written by Les Funtleyder and published by McGraw Hill Professional. This book was released on 2008-12-31 with total page 289 pages. Available in PDF, EPUB and Kindle. Book excerpt: Is your portfolio in peak health? Ranking among the world's largest markets, the $2.5 trillion health care industry is growing at an unprecedented rate. According to Miller Tabak + Co.'s health care strategist Les Funtleyder, major structural renovations to the system are imminent. “Health care is entering an era of reform,” Funtleyder writes, “and with reform comes change and the opportunity for investment gain.” Health-Care Investing provides a thorough explanation of how the industry's mammoth size and complexity can be worked to your advantage and why health care is more resistant to changes in economic cycles than other markets. Funtleyder gives you a comprehensive overview of the industry, from both macro and micro points of view, so you can make informed decisions regarding your investments. You'll find critical information concerning The natural inelasticity of health care and how to profit from it How to take advantage of the market's complexities and inefficiencies Issues and policy changes you need to know The social responsibility aspect of investing in health care Why this market is essential for diversified portfolios In Health-Care Investing, Funtleyder provides the tools you need to dig up the richest opportunities possible and build them into your investment strategy. You'll get a detailed look at traditional market patterns and the events that have shaped--and will continue to shape--the industry. Then you'll find specific strategies you can use to maximize your profits, whether you invest in pharma, biotech, managed services, or a combination of them. This informative and practical guide also includes a list of questions you can use as an investment “template,” which will help guide your decision-making process. With Health Care Investing, you'll be armed with the know-how to make the right decisions today in order to fully capitalize on events of the future.

Download or read book The Pharmagellan Guide to Analyzing Biotech Clinical Trials written by Frank David and published by . This book was released on 2022-01-10 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive primer to help non-experts evaluate clinical studies of new therapies. If you work in or around biotech, you're supposed to understand clinical trial results. But what if you're not an expert in study design or biostatistics? You may feel out of your comfort zone when faced with a journal article, press release, or investor presentation. Inside this book: -- Structured roadmap for assessing the main components of a planned orcompleted biotech trial.-- Clear explanations of the most common concepts and terms in biotechclinical studies, illustrated with over 100 real-world examples.-- Deep dives on essential topics like p values, sample size calculations, andKaplan-Meier curves, written in plain English for non-statisticians.-- Pointers for interpreting positive and negative study results, understandingcommon figures and tables, and identifying red flags in press releases.If you're a biotech executive, investor, advisor, or entrepreneur--or aspire to be one--this handbook will give you the foundation you need to analyze planned and completed clinical trials with more confidence."Hugely helpful. I wish I'd had a book like this earlier in my career." - SIR MENEPANGALOS, Executive VP, Biopharmaceuticals R&D, AstraZeneca"A terrific primer for non-experts looking to better evaluate new therapies." -DAPHNE ZOHAR, Founder and CEO, PureTech Health"Crisp and clear. Wise advice on when to rely on clinical data and when to beskeptical." - MICHAEL ROSENBLATT, Senior Partner, Flagship Pioneering"A source of much-needed illumination." - DAN LEPANTO, Senior ManagingDirector, M&A, SVB Leerink

Download or read book Valuation in Life Sciences written by Boris Bogdan and published by Springer Science & Business Media. This book was released on 2007-03-23 with total page 257 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. It introduces the characteristics of drug and medical device development, explains how to translate these into the valuation, and provides valuable industry data. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.

Download or read book Venture Investing in Science written by Douglas W. Jamison and published by Columbia University Press. This book was released on 2017-06-06 with total page 244 pages. Available in PDF, EPUB and Kindle. Book excerpt: Over the past decade, software companies have increasingly monopolized the flow of venture capital, starving support for scientific research and its transformative discoveries. New medicines, cheaper and faster personal computers, and other life-changing developments all stem from investment in science. In the past, these funds led to steam engines, light bulbs, microprocessors, 3D printers, and even the Internet. In Venture Investing in Science, the venture capitalist Douglas W. Jamison and the investment author Stephen R. Waite directly link financial support to revolutionary advancements in physics, computers, chemistry, and biology and make a passionate case for continued investing in science to meet the global challenges of our time. Clean air and water, cures for intractable diseases, greener public transportation, cheaper and faster communication technologies—these are some of the rich opportunities awaiting venture capital investment today. Jamison and Waite focus on how early-stage companies specializing in commercializing transformative technologies based on deep science have been shunned by venture capitalists, and how the development of such companies have been hampered by structural changes in capital markets and government regulation over the past decade. The authors argue that reinvigorating science-based technological innovation is crucial to reactivating the economic dynamism that lifts living standards and fuels prosperity over time.

Download or read book Biotechnology Entrepreneurship written by Craig Shimasaki and published by Academic Press. This book was released on 2014-04-08 with total page 489 pages. Available in PDF, EPUB and Kindle. Book excerpt: As an authoritative guide to biotechnology enterprise and entrepreneurship, Biotechnology Entrepreneurship and Management supports the international community in training the biotechnology leaders of tomorrow. Outlining fundamental concepts vital to graduate students and practitioners entering the biotech industry in management or in any entrepreneurial capacity, Biotechnology Entrepreneurship and Management provides tested strategies and hard-won lessons from a leading board of educators and practitioners. It provides a 'how-to' for individuals training at any level for the biotech industry, from macro to micro. Coverage ranges from the initial challenge of translating a technology idea into a working business case, through securing angel investment, and in managing all aspects of the result: business valuation, business development, partnering, biological manufacturing, FDA approvals and regulatory requirements. An engaging and user-friendly style is complemented by diverse diagrams, graphics and business flow charts with decision trees to support effective management and decision making. - Provides tested strategies and lessons in an engaging and user-friendly style supplemented by tailored pedagogy, training tips and overview sidebars - Case studies are interspersed throughout each chapter to support key concepts and best practices. - Enhanced by use of numerous detailed graphics, tables and flow charts

Download or read book Valuing Pharmaceutical Companies written by Karen Beynon and published by Woodhead Publishing. This book was released on 2000-06-19 with total page 188 pages. Available in PDF, EPUB and Kindle. Book excerpt: The pharmaceutical sector offers some of the most exciting financial and business opportunities today. This essential and practical guide gives you all the tools you need to assess such opportunities. The second edition of the respected Pharmaceutical Equities, it has been thoroughly revised and updated to reflect the changes, especially in life sciences, since the first edition. The book is international in outlook, and explains the rules of the game not just for wise investing, but also for understanding how this uniquely complex and highly regulated business works. The authors explain: HOW to evaluate the technology and research and development, as well as the sales potential of ensuing products WHAT key issues will affect and influence companies in the next few years HOW to balance potential high returns on breakthrough products against accompanying risks The book begins with a look at the global pharmaceutical industry, from its history to the structure of present day companies. The second part explores how to analyse and value pharmaceutical and biotechnology companies. The final part deals with trading itself and looks at share price movement and the main equity markets throughout the world. Both practical and comprehensive, this handbook will be essential reading for investors, analysers and corporate planners - and is the ONLY book which will show you how to actually value pharmaceutical companies.

Download or read book Assetization written by Kean Birch and published by MIT Press. This book was released on 2020-07-14 with total page 339 pages. Available in PDF, EPUB and Kindle. Book excerpt: How the asset—anything that can be controlled, traded, and capitalized as a revenue stream—has become the primary basis of technoscientific capitalism. In this book, scholars from a range of disciplines argue that the asset—meaning anything that can be controlled, traded, and capitalized as a revenue stream—has become the primary basis of technoscientific capitalism. An asset can be an object or an experience, a sum of money or a life form, a patent or a bodily function. A process of assetization prevails, imposing investment and return as the key rationale, and overtaking commodification and its speculative logic. Although assets can be bought and sold, the point is to get a durable economic rent from them rather than make a killing on the market. Assetization examines how assets are constructed and how a variety of things can be turned into assets, analyzing the interests, activities, skills, organizations, and relations entangled in this process. The contributors consider the assetization of knowledge, including patents, personal data, and biomedical innovation; of infrastructure, including railways and energy; of nature, including mineral deposits, agricultural seeds, and “natural capital”; and of publics, including such public goods as higher education and “monetizable social ills.” Taken together, the chapters show the usefulness of assetization as an analytical tool and as an element in the critique of capitalism. Contributors Thomas Beauvisage, Kean Birch, Veit Braun, Natalia Buier, Béatrice Cointe, Paul Robert Gilbert, Hyo Yoon Kang, Les Levidow, Kevin Mellet, Sveta Milyaeva, Fabian Muniesa, Alain Nadaï, Daniel Neyland, Victor Roy, James W. Williams